|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
HU221584B
(hu)
*
|
1993-01-08 |
2002-11-28 |
Aktiebolaget Astra |
Új vastagbél- (colon) vagy csípőbél- (ileum) specifikus, cukortartalmú szteroidszármazékok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
EP1663999A2
(en)
*
|
2003-08-29 |
2006-06-07 |
Ranbaxy Laboratories, Ltd. |
Inhibitors of phosphodiesterase type-iv
|
|
US20070259874A1
(en)
*
|
2003-11-26 |
2007-11-08 |
Palle Venkata P |
Phosphodiesterase Inhibitors
|
|
CA2561315A1
(en)
|
2004-04-09 |
2005-10-27 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
RU2008119322A
(ru)
*
|
2005-10-19 |
2009-11-27 |
Рэнбакси Лабораториз Лимитед (In) |
Композиции ингибиторов фосфодиэстеразы iv типа
|
|
US20090221664A1
(en)
|
2005-10-19 |
2009-09-03 |
Abhijit Ray |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
EP2066661A2
(en)
*
|
2006-09-22 |
2009-06-10 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
EP2086948A2
(en)
*
|
2006-09-22 |
2009-08-12 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-iv
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
KR20120090100A
(ko)
|
2006-12-26 |
2012-08-16 |
파마시클릭스, 인코포레이티드 |
병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
|
|
DK2805945T3
(da)
|
2007-01-10 |
2019-07-15 |
Msd Italia Srl |
Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
|
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
|
CA2680625C
(en)
*
|
2007-03-14 |
2016-02-23 |
Ranbaxy Laboratories Limited |
Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
|
|
EP2124943A1
(en)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
|
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
CA2773594C
(en)
*
|
2009-09-11 |
2018-09-25 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
AU2010307198C9
(en)
|
2009-10-14 |
2014-02-13 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
EP2534145A4
(en)
|
2010-02-08 |
2013-09-11 |
Kinagen Inc |
THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
|
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2699568A1
(en)
|
2011-04-21 |
2014-02-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
WO2013039488A1
(en)
|
2011-09-13 |
2013-03-21 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
CA2882306A1
(en)
|
2012-08-24 |
2014-02-27 |
Board Of Regents, The University Of Texas System |
Heterocyclic modulators of hif activity for treatment of disease
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
KR20150060724A
(ko)
|
2012-09-28 |
2015-06-03 |
머크 샤프 앤드 돔 코포레이션 |
Erk 억제제인 신규 화합물
|
|
JP6290237B2
(ja)
|
2012-11-28 |
2018-03-07 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
癌を処置するための組成物および方法
|
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3475275B1
(en)
|
2016-06-23 |
2024-04-10 |
Merck Sharp & Dohme LLC |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
EP3525785B1
(en)
|
2016-10-12 |
2025-08-27 |
Merck Sharp & Dohme LLC |
Kdm5 inhibitors
|
|
ES3046537T3
(en)
|
2016-11-08 |
2025-12-02 |
Regeneron Pharma |
Steroids and protein-conjugates thereof
|
|
JP7364471B2
(ja)
|
2017-05-18 |
2023-10-18 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
シクロデキストリンタンパク質薬物コンジュゲート
|
|
AU2018365946B2
(en)
|
2017-11-07 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Hydrophilic linkers for antibody drug conjugates
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3737420A2
(en)
|
2018-01-08 |
2020-11-18 |
Regeneron Pharmaceuticals, Inc. |
Steroids and antibody-conjugates thereof
|
|
CN118955710A
(zh)
|
2018-05-09 |
2024-11-15 |
里珍纳龙药品有限公司 |
抗msr1抗体及其使用方法
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
CA3108388A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US12441730B2
(en)
|
2019-12-17 |
2025-10-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
EP4076459A4
(en)
|
2019-12-17 |
2023-12-20 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
KR20220123229A
(ko)
|
2019-12-17 |
2022-09-06 |
머크 샤프 앤드 돔 엘엘씨 |
Prmt5 억제제
|
|
AU2023336062A1
(en)
|
2022-09-02 |
2025-03-13 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
GEAP202516765A
(en)
|
2022-10-25 |
2025-08-25 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
|
TW202430140A
(zh)
|
2022-12-14 |
2024-08-01 |
美商默沙東有限責任公司 |
奧里斯他汀(auristatin)連接子藥物(payload)、醫藥組合物及其用途
|